CStone Pharmaceuticals’ Sugemalimab Shows Promising Results in Cancer Treatment Study

CStone Pharmaceuticals ( (HK:2616) ) just unveiled an announcement.

CStone Pharmaceuticals has announced the publication of the GEMSTONE-303 study results in the Journal of the American Medical Association, highlighting the efficacy of sugemalimab (Cejemly®) in combination with chemotherapy for treating gastric or gastroesophageal junction adenocarcinoma. The study demonstrated significant improvements in overall survival and progression-free survival for patients with PD-L1 CPS ≥5, positioning sugemalimab as a potential new standard first-line treatment. The results support CStone’s ongoing efforts to expand regulatory approvals and strengthen its position in the oncology market.

More about CStone Pharmaceuticals

CStone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology therapies. The company primarily targets cancer treatment, with a focus on developing monoclonal antibodies for various cancer indications.

YTD Price Performance: 35.22%

Average Trading Volume: 2,808,829

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$3.92B

Find detailed analytics on 2616 stock on TipRanks’ Stock Analysis page.